News about "Eli Lilly and Company "

Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology

Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.

Eli Lilly And Company | 10/02/2026 | By News Bureau

Lilly to Acquire Orna Therapeutics in Up to USD 2.4 Billion Deal to Advance In Vivo CAR-T and Circular RNA Therapies

Lilly’s acquisition of Orna Therapeutics aims to accelerate development of in vivo CAR-T therapies powered by engineered circular RNA and advanced lipid nanoparticle delivery platforms.

Eli Lilly And Company | 10/02/2026 | By News Bureau

Lilly Announces USD 3.5 Billion Injectable Drug and Device Manufacturing Facility in Pennsylvania

Eli Lilly and Company has announced plans to invest USD 3.5 billion to build a new injectable drug and device manufacturing facility in the Lehigh Valley region of Pennsylvania, marking one of the largest life sciences investments in the state’s history.

Eli Lilly And Company | 31/01/2026 | By Darshana |  140

Eli Lilly Appoints New Executives, Expands Senior Leadership Roles to Drive Next Phase of Growth

Eli Lilly has appointed Carole Ho and Adrienne Brown to lead the company’s expansion in neuroscience and immunology, while also broadening the responsibilities of Daniel Skovronsky and Jacob Van Naarden to further strengthen its leadership team.

Eli Lilly And Company | 07/11/2025 | By Dineshwori |  664

Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia

The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.

Eli Lilly And Company | 17/09/2025 | By Dineshwori |  141

Alchemab Launches First-in-Human Trial of ATLX-1282, Secures 32 Million USD Financing Boost

Alchemab Therapeutics, a biopharmaceutical company that develops naturally occurring therapeutic antibodies from resilient individuals, has announced the initiation of its first-in-human phase 1 study of ATLX-1282.

Eli Lilly And Company | 10/09/2025 | By Darshana |  291

Lilly Completes Acquisition of Verve Therapeutics

Eli Lilly and Company has completed its acquisition of Verve Therapeutics, a Boston-based clinical-stage firm developing genetic medicines for cardiovascular disease.

Eli Lilly And Company | 26/07/2025 | By Mrinmoy Dey |  372

Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health

As part of the collaboration, Juvena will leverage JuvNET, the world’s first, fully integrated, AI-enabled screening platform for mapping the therapeutic potential of stem cell-secreted proteins, developed by Juvena.

Eli Lilly And Company | 15/06/2025 | By Darshana |  157

Nimbus Therapeutics Hits Preclinical Research Milestone with Lilly

Throughout their collaboration, Nimbus has leveraged its computational approaches and structure-based drug design capabilities to help overcome these historical obstacles.

Eli Lilly And Company | 26/02/2025 | By Aishwarya |  379

Eli Lilly's Omvoh Shows Long-Term Efficacy in Crohn's Disease: VIVID-2 Study Results Announced

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.

Eli Lilly And Company | 07/02/2025 | By Abha |  447